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Abstract
Background: There has been increasing recognition that osteoarthritis (OA) affects younger individuals who are
still participants in the workforce, but there are only limited data on the contribution of OA pain to work
productivity and other outcomes in an employed population. This study evaluated the impact of OA pain on
healthcare resource utilization, productivity and costs in employed individuals.
Methods: Data were derived from the 2009 National Health and Wellness Survey. Univariable and multivariable
analyses were used to characterize employed individuals (full-time, part-time, or self-employed) ≥20 years of age
who were diagnosed with OA and had arthritis pain in the past month relative to employed individuals not
diagnosed with OA or not experiencing arthritis pain in the past month. Work productivity was assessed using the
Work Productivity and Activity Impairment (WPAI) questionnaire; health status was assessed using the physical
(PCS) and mental component summary (MCS) scores from the SF-12v2 Health Survey and SF-6D health utilities;
and healthcare utilization was evaluated by type and number of resources within the past 6 months. Direct and
indirect costs were estimated and compared between the two cohorts.
Results: Individuals with OA pain were less likely to be employed. Relative to workers without OA pain (n =
37,599), the OA pain cohort (n = 2,173) was significantly older (mean age 52.1 ± 11.5 years vs 41.4 ± 13.2 years; P
< 0.0001) and with a greater proportion of females (58.2% vs 45.9%; P < 0.0001). OA pain resulted in greater work
impairment than among workers without OA pain (34.4% versus 17.8%; P < 0.0001), and was primarily due to
presenteeism (impaired activity while at work). Health status, assessed both by the SF-12v2 and the SF-6D was
significantly poorer among workers with OA pain (P < 0.0001), and healthcare resource utilization was significantly
higher (P < 0.0001) than workers without OA pain. Total costs were higher in the OA pain cohort ($15,047 versus
$8,175; P < 0.0001), driven by indirect costs that accounted for approximately 75% of total costs.
Conclusions: A substantial proportion of workers suffer from OA pain. After controlling for confounders, the
impact of OA pain was significant, resulting in lower productivity and higher costs.
Background
Osteoarthritis (OA) is a degenerative joint disease that
affects almost 27 million adults in the United States
(US) and is ranked among the top three causes of dis-
ability [1,2]. Pathologic features of OA include loss of
articular cartilage and concomitant development of
osteophytes at the joint margins. In the clinical setting,
pain is a major complaint among patients with OA that
also contributes to patient report of reduced joint func-
tion. In line with this, management strategies of OA
include reduction of pain and improvement of function
as the main targets [3-7].
OA has been considered an age-related disease, and
substantial functional impairment, decreased quality of
life, and increased healthcare resource utilization have
been reported among older patients with OA [8-12].
However, there is increasing recognition of the effects of
OA on younger patients who are still participants in the
workforce, and several studies have documented that * Correspondence: alesia.sadosky@pfizer.com
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tivity among employed individuals [13-15].
The importance of lost productivity in arthritis has
recently been highlighted by the endorsement by
OMERACT (Outcome Measures in Rheumatology) of
work as an outcome, although no particular measure
was recommended for its evaluation [16]. While it has
also been suggested that indirect costs related to lost
work productivity are the primary driver of the eco-
nomic burden of OA [17-19], some studies reported
indirect costs that were lower than direct costs [20-22].
S i n c et h e r ea r en os t a n d a r d i zed methods for estimating
indirect costs in OA [23], these contrasting results are
likely due to differences in populations and methodolo-
gies, including inadequately accounting for the contribu-
tion of presenteeism (reduced productivity while at
work) to indirect costs. In fact, presenteeism has been
suggested to be the primary source of lost productive
time and indirect costs among workers with chronic
pain conditions including arthritis [24]. This was
recently demonstrated in a study reporting a consider-
ably increased risk of presenteeism among workers with
arthritis relative to individuals without chronic condi-
tions (odds ratio: 8), whereas the risk of absenteeism
was not increased [25].
In workers with OA, reductions in work productivity,
including presenteeism, appear to be associated with
increased patient-reported OA severity [26], yet data on
the contribution of OA pain to work productivity and
other outcomes in an employed population are limited.
A study by White et al. [21] estimated the economic
burden of patients with OA who were receiving pain
pharmacotherapy, but the relative impact of pain on
costs was not addressed. A more direct effect of OA
p a i nw a sd e m o n s t r a t e di na na n a l y s i so fd a t af r o mt h e
Longitudinal Examination of Arthritis Pain (LEAP)
study [27]. Results from LEAP suggested that weekly
fluctuations in OA pain were associated with changes in
levels of daily activities/functioning, work absenteeism,
sleep interference, and healthcare resource use. In an
analysis of four measures of presenteeism (the Health
and Labor Questionnaire [HLQ]; the Work Limitations
Questionnaire [WLQ]; the World Health Organization’s
Health and Work Performance Questionnaire [HPQ];
and the Work Productivity and Activity Impairment
Questionnaire [WPAI]), Zhang et al. [28] observed a sig-
nificant association between pain and the risk of presen-
teeism, but only weak associations between pain severity
and hours lost. Another study implicated acute pain
exacerbations as a factor in lost productivity in a popu-
lation of employed adults with arthritis, however, the
type of arthritis was not specified [13]. In that study, the
magnitude of lost productivity was mediated by the pro-
portion of workers who lost work time rather than the
amount of time lost. This use of proportions rather than
amount of time was further considered in a combined
OA and rheumatoid arthritis population as part of a
validation study comparing responsiveness of five at-
work productivity measures: the Workplace Activity
Limitations Scale (WALS); the 6-item Stanford Presen-
teeism Scale [SPS-6]; the Endicott Work Productivity
Scale [EWPS]; the Rheumatoid Arthritis Work Instabil-
ity Scale [WIS]; and the Work Limitations Question-
naire [WLQ]) [29]. As indicated by the mean score on
each of the measures, only mild at-work productivity
losses were reported, and the correlations between pain
severity in the past week and scores on the five mea-
sures were only moderate.
To increase our knowledge of the consequences of
OA pain in the workforce, the objective of this study
was to use the National Health and Wellness Survey
(NHWS) to evaluate the impact of OA pain on direct
and indirect costs and health provider visits, as well as
on measures of general health status in an employed
population. The NHWS is a cross-sectional, self-admi-
nistered, internet-based questionnaire administered
annually to a nationwide sample of adults (aged 18 or
older).
Methods
Data source and population
Data were derived from the 2009 National Health and
Wellness Survey (NHWS) that included information on
75,000 individuals in the United States (US). To repre-
sent the demographic composition of the US adult
population, the data are weighted by gender, age and
race/ethnicity http://www.chsinternational.com/nhws.
html.
This analysis was performed using data only for
those respondents who were ≥ 20 years of age and
were currently employed full-time, part-time, or self-
employed. Subjects meeting these criteria were strati-
fied into two cohorts. The first cohort was defined as
workers who self-reported that they have been diag-
nosed with OA and were experiencing arthritis pain in
the past month, and the comparator cohort consisted
of workers who self-reported that they were either not
diagnosed with osteoarthritis or not experiencing
a r t h r i t i sp a i ni nt h ep a s tm o n t h .S e l f - r e p o r to fa nO A
diagnosis was based on two questions. The first ques-
tion determined whether the subject had been diag-
nosed with arthritis by a physician (response of yes/
no), and the second question elicited the type of
arthritis that the subject has, with potential responses
of osteoarthritis, rheumatoid arthritis, psoriatic arthri-
tis, and not sure. No clinical information (e.g., X-ray
findings) was asked of participants to define the pre-
sence of OA.
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The demographic and health characteristics of the two
cohorts were characterized and compared. These char-
acteristics included age, gender, race/ethnicity, marital
status, education, income, insurance status, employment
type, body mass index (BMI), and Charlson Comorbidity
Index (CCI) [30].
Work productivity was assessed using the Work Pro-
ductivity and Activity Impairment (WPAI) questionnaire
[31]. The WPAI is a self-reported questionnaire consist-
ing of four subscales that evaluate absenteeism, presen-
teeism, overall work impairment, and activity
impairment during the previous seven days, generated
in the form of percentages, with higher values indicating
greater impairment. The WPAI used in the current ana-
lysis was not specific for OA.
Health-related quality of life was assessed using the
physical (PCS) and mental component summary (MCS)
scores from the self-reported SF-12v2 Health Survey
[32]. Scores for the PCS and MCS are normed to the
US population (mean = 50, SD = 10) and vary from 0 to
100, with higher scores indicating better quality of life.
Additionally, health utility scores for both cohorts were
calculated using the SF-6D [33], which provides a pre-
ference-based single index measure for health status and
varies from 0.29 to 1.
Healthcare utilization, regardless of cause, was eval-
uated by type and number of resources that the
patients reported using within the past six months.
These resources included number of prescriptions and
provider visits for both traditional healthcare (physi-
cian, emergency room [ER], and hospitalizations) and
non-traditional healthcare e.g., acupuncturist, herbal-
ist, etc.
The direct medical costs evaluated in this analysis
included only traditional provider visits (i.e. physician,
ER, and hospitalizations). These costs were estimated by
multiplying the units of resource categories for six
months by the average cost of the resource derived
from the Medical Expenditure Panel Survey database
[34-36], and then multiplying by two to project annual
costs. Indirect costs associated with lost productivity for
any reason were calculated among both cohorts using
the method of Lofland et al. [37] based on data from
the WPAI and median annual income values obtained
through the Bureau of Labor Statistics (BLS) [38]. For
each respondent, the percent overall work impairment
(obtained from the WPAI) was multiplied by the annual
income. Direct and indirect costs were summed to pro-
vide an estimate of total costs.
Statistical analyses
Univariable analysis was used to examine differences in
demographic and clinical characteristics between the
two groups. Analysis of quality of life and work produc-
tivity were performed using multivariable models with
the following demographic and clinical characteristics as
covariates: age range (coded as 20-39 vs. 40-64 and ≥ 65
years), gender, race/ethnicity (coded as non-Hispanic
white, non-Hispanic black, Hispanic, or other), educa-
tion (more than high school vs. high school equivalent
degree or less), income (< $25 K, $25 K to < $50 K, $50
K to < $75 K, ≥ $75 K, or decline to answer), CCI (0 vs.
≥ 1), health insurance (yes vs.n o ) ,B M I( u n d e r w e i g h t ,
normal, overweight, obese, or decline to answer),
employment (full-time, part-time, or self-employed), tra-
ditional healthcare visits (yes vs. no), non-traditional
healthcare visits (yes vs. no), prescription drug use (yes
vs. no), ER visits (yes vs. no), and hospitalization (yes vs.
no).
Determination and analysis of costs were not adjusted
for covariates. Generalized linear models (GLMs) were
conducted to estimate work productivity and activity
impairment using a negative binomial distribution to
account for skewness and provide best fit. Significant
differences between the two groups were examined
using Wald chi-square tests for categorical outcomes
and independent-samples t-tests for continuous out-
comes. For all analyses, a P value < 0.05 was considered
statistically significant.
Results
Of the 39,772 workers who met the inclusion criteria,
2,173 were diagnosed with OA and experienced arthritis
pain in the past month, and thus were included in the
OA pain cohort. The peripheral joints (ankles, elbows,
feet, fingers, hands, hips, knees, neck, shoulders, wrists,
other) were affected in 98.1% of these patients, and the
spine was affected in 43.7%. The comparator cohort
consisted of workers not diagnosed with osteoarthritis
or not experiencing arthritis pain in the past month (n
= 37,599), with 10.7% and 2.5% reporting peripheral and
spinal involvement, respectively.
Weighted univariable analysis of demographic charac-
teristics showed that workers in the OA pain cohort
were not only significantly older than the comparator
group (mean 52.1 ± 11.5 vs 41.4 ± 13.2 years; P <
0.0001), but also had a greater comorbidity burden as
indicated by the CCI (mean 0.8 ± 1.2 vs 0.3 ± 0.9; P <
0.0001). Additionally, workers in the OA pain cohort
tended toward obesity (BMI ≥ 30); mean BMI 31.0 ± 7.4
vs 28.2 ± 6.7 (P < 0.0001). As shown in Table 1, there
was a significantly greater proportion of females in the
OA pain cohort (58.2 vs 45.9%; P < 0.0001), and while
both cohorts were predominantly non-Hispanic and
White, this demographic had greater representation in
the OA pain group. Significantly lower proportion of
workers with OA pain reported full-time employment
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between cohorts in level of education.
Health status, as described by the PCS and MCS sum-
mary components of the SF-12v2 (Figure 1A) and SF-
6D health utility scores adjusted for covariates (Figure
1B) was significantly lower among workers with OA
pain (P < 0.0001). For the SF-12v2, the difference
between cohorts was greater for the PCS. In multivari-
able analysis after controlling for covariates, these signif-
icant differences were maintained, with PCS and MCS
scores that were lower in the OA pain cohort by 7.6
(95% CI 8.0, 7.3) and 1.2 (95% CI 1.6, 0.8) points,
respectively, and 0.07 points lower (95% CI, 0.08, 0.07)
for the SF-6D.
Health resource utilization reported by workers over
the previous 6-month period and adjusted for covariates
was significantly higher in the OA pain cohort than
comparators across provider visit categories including
use of non-traditional healthcare (Figure 2). Addition-
ally, workers with OA pain were currently prescribed a
mean of 5.3 ± 4.9 medications, more than twice that of
workers without OA pain, 2.1 ± 3.4 (P < 0.0001).
As shown in Figure 3, adjusted work and activity was
impaired to a significantly greater extent in the OA pain
cohort relative to the comparator cohort. While in both
cohorts, lost productivity due to presenteeism was almost
4-times greater than that due to absenteeism, both percent
presenteeism and percent absenteeism were significantly
Table 1 Weighted univariable statistics (to reflect the US population) for demographic characteristics of workers with
OA pain compared with workers without OA pain
Variable OA Pain (n = 2,173) Without OA pain (n = 37,599) P
n Weighted percent (SE) n Weighted percent (SE)
Age range
20-39 years 267 14.5 ± 0.8 16,123 47.7 ± 0.3 < 0.0001
40-64 years 1,453 71.8 ± 1.1 18,571 47.8 ± 0.3 < 0.0001
≥ 65 years 453 13.7 ± 0.9 2,905 4.5 ± 0.1 < 0.0001
Gender
Male 954 41.8 ± 1.1 19,824 54.1 ± 0.3 < 0.0001
Female 1,219 58.2 ± 1.1 17,775 45.9 ± 0.3 < 0.0001
Race/ethnicity
White, non-Hispanic 1,792 78.0 ± 1.1 26,347 66.5 ± 0.3 < 0.0001
Black, non-Hispanic 169 8.4 ± 0.8 4,434 12.1 ± 0.2 < 0.0001
Hispanic 99 8.3 ± 0.8 3,569 14.6 ± 0.2 < 0.0001
Other 113 5.3 ± 0.5 3,249 6.8 ± 0.1 0.0032
Education
High school graduate or less 376 17.9 ± 0.9 6,211 16.9 ± 0.2 0.3053
More than high school 1,797 82.2 ± 0.9 31,387 83.1 ± 0.2 0.3067
Income
< $25,000 294 13.5 ± 0.8 4,205 11.6 ± 0.2 0.0183
$25,000 to $49,999 667 30.4 ± 1.1 10,807 29.1 ± 0.3 0.2218
$50,000 to $74,999 533 24.8 ± 1.0 9,109 24.2 ± 0.2 0.5271
≥ $75,000 579 26.5 ± 1.1 11,830 30.9 ± 0.3 <.0001
Decline to answer 100 4.8 ± 0.5 1,648 4.2 ± 0.1 0.2813
Employment
Full time 1,200 57.3 ± 1.2 26,088 70.7 ± 0.3 < 0.0001
Part time 552 23.9 ± 1.1 7,139 18.3 ± 0.2 < 0.0001
Self-employed 421 18.8 ± 0.9 4,372 11.0 ± 0.2 < 0.0001
Health insurance
Yes 1,880 85.4 ± 0.8 31,143 81.8 ± 0.2 < 0.0001
No 293 14.6 ± 0.8 6,456 18.2 ± 0.2 < 0.0001
BMI
Underweight 19 0.8 ± 0.2 629 1.7 ± 0.1 < 0.0001
Normal 416 20.1 ± 1.0 11,889 32.1 ± 0.3 < 0.0001
Overweight 660 30.0 ± 1.1 12,679 33.6 ± 0.3 0.0011
Obese 1,044 47.5 ± 1.2 11,737 30.9 ± 0.3 < 0.0001
Decline to answer 34 1.5 ± 0.3 665 1.8 ± 0.1 0.403
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Workers with OA pain reported losing 31% of productive
time while at work and 8% through absenteeism, compared
with comparators who lost 16% of productive time while at
work and 4% through absences (P < 0.0001 for both com-
parisons). The ratio differences shown in Figure 4B indicate
the magnitude of impairment for the OA cohort relative to
the comparator group; for all outcomes, lost productivity
and impairment was almost twice as high in the OA pain
cohort (P < 0.0001 for all ratio differences). In terms of
actual hours, workers with OA pain lost a mean of 2.7 ± 7.1
hours during the past week due to absenteeism, and a mean
of 9.7 ± 9.7 hours due to presenteeism. In contrast, the
comparator cohort lost 1.4 ± 5.6 and 5.2 ± 8.6 hours to
absenteeism and presenteeism, respectively; P < 0.0001 for
both comparisons with the OA pain cohort.
All presented costs represent actual costs unadjusted
for covariates. Direct medical costs were significantly
higher in the OA pain cohort across all provider cate-
gories (Figure 4A), resulting in total direct medical costs
that were more than 1.5-times higher than for the com-
parator group, $3,702 vs $2,158 (P < 0.0001). In both
cohorts, hospitalization costs accounted for slightly
more than half of the direct costs, 51% and 55% for OA
pain and the comparator, respectively. Total costs were
almost twice as high among workers with OA pain
cohort as in workers without OA pain, $15,047 and
$8,175, respectively (P < 0.0001), and were primarily dri-
ven by indirect costs resulting from lost productivity.
Discussion
This study not only confirms the substantial presence
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Page 5 of 9been suggested by other studies [14,15,21], but supports
other evidence that OA pain is a contributory factor to
the economic and individual worker burden. Notably,
among the employed population that served as the basis
for this study, the prevalence of workers with OA who
had arthritis pain during the past month was greater
than 5%. Although pain is primary symptom of OA, it is
likely that the comparator cohort contained a propor-
tion of workers with OA who did not have pain in the
past month, suggesting that the overall presence of OA
in the workforce is likely to be higher.
While the demographics of the OA pain cohort relative
to the comparator were generally consistent with what
might be expected for OA, i.e. older and female, the
mean age of the OA pain cohort (52 years) nevertheless
demonstrates the presence of OA in a younger demo-
graphic having a potential for additional years of work-
force participation.
Workers with OA pain reported significantly lower
health status than the comparator cohort even after
adjusting for relevant covariates. Not surprisingly, since
OA and pain affects physical functioning, there was a
greater effect on physical components of health status,
although the difference in mental components was also
significant. The health utility score was also significantly
lower among the workers with OA pain relative to the
comparators; health utility scores are important from
the economic perspective since they are frequently
incorporated into economic analyses. The adjusted dif-
ference between cohorts on the SF-12v2 PCS score (7.6
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exceeded the values that are considered clinically mean-
ingful; > 3 and 0.03 points, respectively [39,40].
The data also show that workers with OA pain had
more health provider visits across categories and were
prescribed twice as many medications than the com-
parator cohort, although whether these visits or medica-
tions were specifically related to pain could not be
ascertained. It is also interesting to note that non-tradi-
tional health resources were used by a greater propor-
tion of individuals with OA pain, since these visits may
not necessarily be covered by insurance plans.
Workers with OA pain were characterized by signifi-
cantly greater work and activity impairment relative to
comparators. In the OA pain cohort overall, approxi-
mately one-third (34%) of worker productivity was lost.
Presenteeism has been a neglected component of asses-
sing lost productivity, and is an outcome that can best
be captured by studies that are based on patient report.
As far as we can ascertain, this is the first study in OA
that evaluated presenteeism in a complete context of
worker impairment along with absenteeism. Consistent
with the results suggested by the literature on the gen-
eral arthritis population [13,24,25,41], presenteeism was
the primary source of work impairment, with almost 10
hours per week lost while at work; almost 4-fold greater
than for absenteeism.
A number of measures of productivity are available
that include assessment of presenteeism, and a recent
study has shown variability in the ability of four of these
measures, including the WPAI, to estimate presenteeism
[28]. However, among the four measures, the WPAI was
the only one having a complete response rate, possibly
related to its brevity and ease of use; several of the
other measures are associated with an administration
burden because of their length. It is for this reason that
the WPAI is among the most commonly used produc-
tivity measures, and was considered appropriate for the
current study. Additionally, the significant association
between pain and presenteeism observed in that study
further suggests that the high burden of lost productiv-
ity observed in our OA pain cohort is due at least in
part to the pain component [28].
Mean annual unadjusted costs in the OA pain cohort,
which were significantly higher than the comparator
cohort, reflected the substantial impact of lost produc-
tivity, with estimated indirect costs of $11,345. These
indirect costs account for approximately 75% of total
costs, and are almost twice as high as the indirect costs
of the comparator cohort ($6,017). Interestingly, among
workers without OA pain, indirect costs accounted for a
similar proportion of total costs, suggesting the general
importance of lost productivity in economic evaluations
of health and disease. For direct costs, although only
10% of the OA pain cohort reported hospitalizations,
this resource category was the primary cost driver, most
likely due to the high cost per event.
All outcomes, except for costs, were adjusted for rele-
vant covariates. Since many factors (such as age, ethni-
city, gender, socioeconomic status, and insurance) are
likely to impact health care seeking behavior by patients
and management strategies by providers, caution should
be applied when interpreting the implications of the
above cost analysis. Future cost analyses controlling for
such covariates may yield slightly different estimates.
Limitations
Although strengths of this study that may enhance its
generalizability include a large sample size and popula-
tion-level analysis based on a weighted assessment to
reflect the demographic composition of the US popula-
tion, there are certain limitations that need to be con-
sidered. An important limitation is that the data used in
the analyses are based on patient self-report, without
clinical verification of an OA diagnosis, and thus are
subject to the biases that are inherent in this type of
data presentation. It is possible that some patients
reported that they were diagnosed with OA when, in
fact, they were not. Conversely, some patients may have
thought they were diagnosed with another condition
when, in fact, it was OA. As a result, additional error
could have been introduced into the analyses. Neverthe-
less, as previously noted, patient report provides an
important source for evaluating outcomes, and is the
primary means of determining presenteeism.
Since this was part of a large general health survey, the
version of the WPAI that was used was not OA specific.
Therefore, the observed relationships between OA pain
and productivity should be considered associative rather
than causal, since direct causality cannot be inferred
regarding the OA pain as a source of lost productivity,
especially given that workers with OA pain were charac-
terized by a significantly greater comorbidity burden than
workers without OA pain. Similarly, the higher resource
utilization and costs cannot be ascribed specifically to the
OA nor the pain, since there are no claims linking
resource use with the disease and symptoms of interest.
Nevertheless, lost productivity in the OA pain cohort was
twice as high as the comparator cohort, with both total
costs and indirect costs also almost twice as high, sug-
gesting a substantial burden associated with OA pain
that may be of special concern to employers.
Another limitation was that the questionnaire cap-
tured neither the type of employment nor the specific
site of OA pain. Since these variables are likely to
impact productivity as well as management strategies,
their absence may reduce the generalizability of the
results.
DiBonaventura et al. BMC Musculoskeletal Disorders 2011, 12:83
http://www.biomedcentral.com/1471-2474/12/83
Page 7 of 9Because the source of our data was not a medical
claims database, only the number of prescribed drugs by
patient report was captured, and our inability to estimate
the costs associated with pharmacotherapy for inclusion
in direct costs is another limitation. However, extrapolat-
ing from a study that reported total pharmacotherapy
costs of $2,941 among patients with OA receiving pain
therapy [21], and adding these costs to the direct costs
for provider visits estimated in the current study would
result in total direct costs that are approximately half of
the indirect costs. Our derivation of annual costs was
based on extrapolation of 6 month data to 1 year. How-
ever, this method may not adequately reflect actual
resource utilization over a 12-month period.
Conclusions
Results from this study highlight the fact that OA pain
is not necessarily relegated to an older population, but
i sp r e s e n ti na nu n d e r - r e c o g n i z e dp r o p o r t i o no ft h e
w o r k f o r c e .D e s p i t et h ea b o v el i m i t a t i o n s ,t h ed a t as h o w
that presence of OA pain has a profound impact on
quality of life, work productivity, and healthcare
resource use among workers. Even after controlling for
confounding variables, workers with OA pain reported
significantly reduced health status and significant work
impairment. Notably, this study also demonstrated the
importance of presenteeism as a contributing factor to
lost productivity. These combined factors resulted in
costs that were significantly higher than among workers
without OA pain, and were driven by indirect costs,
which appeared to primarily result from work impair-
ment that occurred while at work (presenteeism) rather
than absence from work. These results not only expand
our knowledge of the burden of OA, but they can also
inform employers and health care providers on the con-
tribution of OA pain to patient productivity and quality
of life. Such information may potentially be of use when
considering how to evaluate management strategies for
alleviating the worker and employer burdens associated
with this condition in the general population.
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